These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20159003)

  • 1. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?
    Ata B; Urman B
    Reprod Biomed Online; 2010 Jan; 20(1):165-6; author reply 167. PubMed ID: 20159003
    [No Abstract]   [Full Text] [Related]  

  • 2. GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial.
    Fusi FM; Brigante CM; Zanga L; Mignini Renzini M; Bosisio C; Fadini R
    Reprod Biol Endocrinol; 2019 Nov; 17(1):103. PubMed ID: 31783862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the clinical utility of GnRH antagonist to GnRH agonist in an oocyte donation program.
    Sauer MV; Paulson RJ; Lobo RA
    Gynecol Obstet Invest; 1997; 43(4):215-8. PubMed ID: 9194617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing stimulation requirements and final outcome between early follicular and mid luteal pituitary suppression in the long gonadotropin releasing hormone agonist protocol.
    Sarhan A; Harira M; Elshazly S; Nouh A
    JBRA Assist Reprod; 2016 May; 20(2):59-61. PubMed ID: 27244762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
    Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
    Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of duration of the GnRH agonists in the luteal phase in the outcome of assisted reproduction cycles.
    Geber S; Sampaio M
    Gynecol Endocrinol; 2013 Jun; 29(6):608-10. PubMed ID: 23656392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mid-luteal phase GnRH agonist on frozen-thawed embryo transfers during natural menstrual cycles: a randomised clinical pilot study.
    Seikkula J; Anttila L; Polo-Kantola P; Bloigu R; Engblom J; Tinkanen H; Jokimaa V
    Gynecol Endocrinol; 2016 Dec; 32(12):961-964. PubMed ID: 27348542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.
    Razieh DF; Maryam AR; Nasim T
    Taiwan J Obstet Gynecol; 2009 Sep; 48(3):245-8. PubMed ID: 19797013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys.
    Navot D; Rosenwaks Z; Anderson F; Hodgen GD
    Fertil Steril; 1991 Jun; 55(6):1069-75. PubMed ID: 1828042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
    Kovacs M; Schally AV
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study.
    Ata B; Yakin K; Balaban B; Urman B
    Hum Reprod; 2008 Mar; 23(3):668-73. PubMed ID: 18192671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midluteal gonadotropin-releasing hormone analog administration in early pregnancy.
    Ron-El R; Golan A; Herman A; Raziel A; Soffer Y; Caspi E
    Fertil Steril; 1990 Mar; 53(3):572-4. PubMed ID: 2137797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
    Zhao LJ; Wei LH; Li XP; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.